Sionna Shares Tumble After Cystic-Fibrosis Treatment Unexpectedly Misses Endpoint
Dow Jones2026/08/10 13:07By Connor Hart
Shares of Sionna Therapeutics tumbled after the company said a midstage, proof-of-concept trial of its treatment for cystic fibrosis didn't meet its key activity endpoint.
The stock lost nearly 90% of its value in premarket trading Monday, falling to $5.27. Shares ended Friday's regular session at $51.04, up 24% year to date.
The biopharmaceutical company said before the bell that potential confounders were observed in the trial, such as higher-than-anticipated levels of variability in individual sweat chloride levels.
"We are disappointed in the unexpected results from the Phase 2a trial," Chief Executive Mike Cloonan said. "We are further evaluating the data to decide on next steps for the SION-451 dual combination."
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 10, 2026 09:07 ET (13:07 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
PAMT Insider Bought Shares Worth $31,225,740, According to a Recent SEC Filing
Alpha Metallurgical Resources Insider Bought Shares Worth $2,258,289, According to a Recent SEC Filing
Indah Prakasa Sentosa controller PT Graha Inti Guna Persada cuts stake to 79.02% from 87.48%
Heliad invests in character robotics startup Dynamic Creatures
Crypto prices
More
